BMPR2 and cancer: These studies also suggest that resistance to BMPR2 inhibitors may occur in cancer cells that do not express BMPR2 at the plasma membrane and/or the inhibitor does not cause BMPR2 to be mislocalized to the cytoplasm and/or lysosome for degradation.